Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan during weaning from venoarterial extracorporeal membrane oxygenation
2023-508024-36-00Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of levosimendan in cardiogenic shock (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Change in left ventricular outflow tract velocity time integral. Started Jul 2024; status: completed.
02
Drugs
levosimendan
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on 2023-508024-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508024-36-00.